FI
FCPM III Services B.V.
13F filer · CIK 0002013410Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$750MU.S. long equity reported on 13F
Positions111 new · 0 closed
Net flow last quarter-$12.9MBuys minus sells
Top 10 positions weight99.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202611 positions | |||||
| $288M | 38.34% | 7.22% | -7.7% | Q4 2023 | |
| $116M | 15.41% | 7.10% | Not reported | Q4 2025 | |
| $85.5M | 11.39% | 2.32% | -17.1% | Q4 2023 | |
| $75.8M | 10.10% | 7.56% | Not reported | Q3 2025 | |
| $63.5M | 8.46% | 3.95% | Not reported | Q1 2026 | |
| $31.1M | 4.14% | 3.34% | Not reported | Q4 2023 | |
| $30.2M | 4.02% | 6.05% | Not reported | Q4 2025 | |
| $28.8M | 3.84% | 3.92% | New | Q2 2026 | |
| $16.7M | 2.22% | 14.38% | Not reported | Q4 2023 | |
| $14.7M | 1.96% | 4.97% | Not reported | Q2 2024 | |
| $834K | 0.11% | Not reported | Not reported | Q4 2023 | |
| Q1 2026Reported May 15, 202610 positions | |||||
| $294M | 40.77% | 7.89% | Not reported | Q4 2023 | |
| $84.2M | 11.66% | 2.81% | -15.0% | Q4 2023 | |
| $73.5M | 10.17% | 7.60% | +13.8% | Q3 2025 | |
| $65.6M | 9.08% | 14.38% | Not reported | Q4 2023 | |
| $65.6M | 9.08% | 7.14% | Not reported | Q4 2025 | |
| $63.2M | 8.75% | 4.05% | New | Q1 2026 | |
| $30.8M | 4.27% | 6.09% | Not reported | Q4 2025 | |
| $21.5M | 2.97% | 3.40% | Not reported | Q4 2023 | |
| $16.1M | 2.23% | 4.98% | Not reported | Q2 2024 | |
| $7.28M | 1.01% | Not reported | Not reported | Q4 2023 | |
| Q4 2025Reported Feb 17, 202610 positions | |||||
| $323M | 42.30% | 8.04% | -0.2% | Q4 2023 | |
| $107M | 14.01% | 3.31% | Not reported | Q4 2023 | |
| $87M | 11.40% | 14.38% | Not reported | Q4 2023 | |
| RTRAPTRAPT Therapeutics, Inc. | $62.1M | 8.14% | 6.62% | +432.6% | Q2 2025 |
| $56.7M | 7.43% | 7.33% | New | Q4 2025 | |
| $47.3M | 6.20% | 9.34% | +852.8% | Q3 2025 | |
| $27.3M | 3.58% | 3.53% | -32.5% | Q4 2023 | |
| $24.6M | 3.22% | 5.00% | +0.5% | Q2 2024 | |
| $19.9M | 2.61% | 6.09% | New | Q4 2025 | |
| $8.52M | 1.12% | Not reported | Not reported | Q4 2023 | |
| Q3 2025Reported Nov 14, 20259 positions | |||||
| $262M | 52.36% | 8.14% | -13.4% | Q4 2023 | |
| $69.1M | 13.81% | 3.83% | Not reported | Q4 2023 | |
| $65.8M | 13.15% | 18.82% | Not reported | Q4 2023 | |
| ATATXSAstria Therapeutics, Inc. | $29.9M | 5.98% | 7.28% | Not reported | Q4 2024 |
| $26.7M | 5.34% | 4.98% | Not reported | Q2 2024 | |
| $18.5M | 3.70% | 4.21% | New | Q3 2025 | |
| $17.4M | 3.48% | 5.30% | +6.4% | Q4 2023 | |
| RTRAPTRAPT Therapeutics, Inc. | $8.88M | 1.77% | 2.08% | -21.8% | Q2 2025 |
| $2.07M | 0.41% | Not reported | Not reported | Q4 2023 | |
Premium opens every quarter this fund has filed